The phase II RAMONA trial enrolled 66 older ESCC patients with recurrent disease in second-line therapy: 67% of these patients received nivolumab and ipilimumab (anti-CTL-A4), and received 33% nivolumab alone [105]. Here, CTLA4 is linked to esophageal squamous cell carcinoma.